TCGA-CV-A464-01A-11R-A266-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- MYOGENESIS+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- INTERFERON_GAMMA_RESPONSE+0.410
- NOTCH_SIGNALING+0.210
- PANCREAS_BETA_CELLS+0.210
- APICAL_SURFACE+0.150
- COAGULATION+0.150
- UV_RESPONSE_DN+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
Top 10 suppressed
- MITOTIC_SPINDLE-0.370
- G2M_CHECKPOINT-0.360
- CHOLESTEROL_HOMEOSTASIS-0.340
- E2F_TARGETS-0.340
- MTORC1_SIGNALING-0.260
- PI3K_AKT_MTOR_SIGNALING-0.260
- ANDROGEN_RESPONSE-0.240
- MYC_TARGETS_V1-0.220
- PROTEIN_SECRETION-0.210
- SPERMATOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932812 | — | — | 0.774 |
| 2 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.773 |
| 3 | TCGA-BH-A0B2-01A-11R-A10J-07 | — | A | 0.742 |
| 4 | 20030012.LumA | — | A | 0.718 |
| 5 | MNG1108 | — | — | 0.717 |
| 6 | TCGA-XF-A9SK-01A-11R-A42T-07 | — | — | 0.717 |
| 7 | SRR1797234 | — | cohortMD2 | 0.716 |
| 8 | MNG585 | — | — | 0.711 |
| 9 | TCGA-CQ-6224-01A-11R-1915-07 | — | — | 0.709 |
| 10 | MDT-AP-1340 | Med | Medulloblastoma | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| MYOGENESIS | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |